Leah Lawrence

Switching from intravenous to subcutaneous administration of rituximab for non-Hodgkin diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) resulted in similar efficacy with no new safety issues.

The international retrospective study included 365 patients with newly diagnosed early-stage follicular lymphoma rigorously staged with PET-CT and bone marrow biopsy.

A survey of physicians found recruiting for trials through social media can be useful, but not for cancer therapeutic trials.

CAR T cells are a more effective therapy if manufactured for patients with multiple myeloma prior to the onset of relapsed or refractory disease.

Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.

A combination of pegilodecakin (pegylated IL-10) with an anti-PD-L1 monoclonal antibody inhibitor showed preliminary antitumor activity.

After the FDA restricted the labels of 2 drugs used to treat bladder cancer, oncologists' use of these treatments decreased drastically.

Two studies from ESMO have potentially found treatments which can improve survival in HR-positive breast cancer.

Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.

MYC-rearrangement within 2 years after diagnosis may affect the prognosis of patients with diffuse large B-cell lymphoma.

Researchers examined whether cancer or treatment type impacted the symptom burden of survivors of cancer.

A new study looks into whether disease stage at diagnosis affects the occurrence and location of a second primary malignancy in DLBCL.

The ACHIEVE study is one of six that are part of a global collaborative effort to evaluate the noninferiority of 3-month vs 6-month oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer.

A new study looked at median overall survival for patients with prior antibiotic therapy compared with patients with no prior antibiotic therapy.

Researchers conducted a study to determine if low levels of immune infiltration were associated with inferior outcomes among patients with follicular lymphoma.

A new study evaluated whether the m7-FLIPI score in patients with follicular lymphoma treated with rituximab without chemotherapy can indicate prognosis.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Researchers assessed whether patients with head and neck cancer who had higher levels of tumor-infiltrating lymphocytes had better survival rates.

Data from a new study show the importance of taking preventative measures against contracting human papillomavirus, including urging patients to get the HPV vaccine.

Underinsured patients use websites like GoFundMe to pay medical bills after being diagnosed with cancer, but many fundraising campaigns are unsuccessful.

Patients with multiple myeloma whose disease progresses on BCMA-targeted therapy can possibly respond to a different BCMA-targeted therapy.

Researchers compared the demographics of patients in Oregon and Washington seeking medical aid in dying.

Delays in CAR T-cell therapy may significantly decrease gains in survival and productivity for patients with diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia.

Researchers analyzed data from 108,647 postmenopausal women diagnosed with breast cancer to see if there was an increased risk of the disease for those who used menopausal hormone therapy.

Researchers looked at the pre-transplant PET/CT Deauville scores of patients with relapsed or refractory diffuse large B-cell lymphoma treated with R-DHAC to see if patients with a higher score had a higher risk for treatment failure.

A new study surveyed 1,246 patients on whether they'd be willing to share electronic health records and biospecimens for research.

Many trials in the last decade that have led to FDA drug approvals didn't report on race and the ones that did were lacking in racial diversity.